Integrating Ide-Cel Into Pretreated Multiple Myeloma Regimens: Shaji Kumar, MD

Video

The hematologist from Mayo Clinic discussed the integration of CAR T-cell therapy into the treatment paradigm for heavily pretreated multiple myeloma.

This content originally appeared on our sister site, OncLive.

Idecabtagene vicleucel (ide-cel; Abecma) was approved by the FDA on March 26, 2021 as the first BCMA-directed CAR T-cell therapy for patients with relapsed/refractory multiple myeloma who progressed on 4 or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and a CD38-directed monoclonal antibody.

OncLive spoke with Shaji K. Kumar, MD, a consultant in the Division of Hematology and a professor of medicine with Mayo Clinic, about the integration of CAR T-cell therapy into the treatment paradigm for heavily pretreated multiple myeloma.

For now, ide-cel will likely be reserved as an option for patients with triple-class refractory disease, says Kumar. As such, ide-cel is competing against other FDA-approved agents, such as belantamab mafodotin-blmf (Blenrep), selinexor (Xpovio), and melphalan flufenamide (melflufen; Pepaxto), Kumar explains.

Notably, if given the option, many providers would select CAR T-cell therapy over belantamab mafodotin, selinexor, or melflufen because ide-cel demonstrated a high rate of durable responses in patients with heavily pretreated multiple myeloma, Kumar says. However, like the lymphoma paradigm, the reimbursement protocol for ide-cel will not be fully realized for 1 to 3 more years, which limits the treatment’s utility, concludes Kumar.

Related Videos
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
© 2024 MJH Life Sciences

All rights reserved.